中文摘要：

CD4＋CD25＋Foxp3＋调节性T细胞可以有效抑制同种异体反应时细胞介导的免疫反应,近年来是器官移植领域学者关注热点之一。既往研究表明,Tregs既存在于移植器官受体的各级淋巴组织中,而且也分布在移植物内部中。因为Tregs的活化位置不同,其免疫抑制功能也不同,如果Tregs用来预防免疫排斥反应的话,那么Tregs在体定位和迁移信息特别关键。趋化因子受体是CD4＋CD25＋Foxp3＋Treg进行靶向迁移、在特定部位发挥免疫调节作用的结构基础。Tregs在体迁移是一个由多个细胞、多种趋化因子及其受体参与的运动过程。随着淋巴组织中新的趋化因子受体和Tregs特异性趋化因子的发现,提示Tregs在体复杂的迁移过程和活化主要是由趋化因子及受体介导。因此,趋化因子领域的研究将会为器官移植病人提供新的治疗思路。

英文摘要：

CD4＋CD25＋Foxp3＋ regulatory T cells can effectively inhibit the immune response induced by the cell mediated immune response. In recent years, it is one of the hot spots in the field of organ transplantation. Previous studies have indicated that Tregs is not only found in the lymphoid tissues of transplanted organs, but also in the interior of the graft. Because the activation of Tregs is different, its immune suppression function is also different. If Tregs is used to prevent immune rejection, positioning and migration information is particularly critical. Chemokine receptors expression has been known to be important for lymphocyte homing to lymph nodes, and also contributes to chemokine-induced leukocyte migration within extravascular tissues. Preclinical studies clearly demonstrate that Tregs cells play an important role in transplantation tolerance induction, attracting most attention of investigators.